Novel ligands balance estrogen receptor β and α agonism for safe and effective suppression of the vasomotor response in the ovariectomized female rat model of menopause.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (ovariectomized rats).
PubMed 24823389 · doi:10.1210/en.2013-1976
What was done
Researchers evaluated novel synthetic estrogen receptor ligands lacking the B ring of estradiol (A-CD compounds) with varying ERβ:ERα binding ratios in an ovariectomized female rat model of menopausal hot flashes. They tested compound L17 (ERβ:ERα relative binding affinity 9.3), TD3 (ERβ:ERα affinity 5.0), TD81 (ERα:ERβ affinity 15.2), and 17β-estradiol (E2). Measured outcomes included diurnal/nocturnal tail-skin temperatures (TSTs), uterine weight and mammary tissue proliferation, body weight, metabolic stability, and hypothalamic median preoptic nucleus c-fos induction.
What was found
At 1 mg/kg, TD81 was ineffective for temperature regulation, while L17 showed a trend toward TST reduction. Both E2 and TD3 reduced TSTs but caused marked proliferative effects on mammary and uterine tissues. At 2 mg/kg, L17 reduced TSTs more effectively than E2 with minimal effects on uterine weight and mammary tissue. Both E2 and L17 produced similar body weight reduction and comparable c-fos expression in the median preoptic nucleus. L17 demonstrated 2-fold greater metabolic stability compared to E2.
Why it matters
This study provides proof-of-concept that preferential ERβ agonism with fractional ERα activity can suppress vasomotor symptoms without triggering typical estrogenic proliferative risks in reproductive tissues.
Limits
The study was conducted entirely in an ovariectomized rat model, and the abstract omitted sample sizes. Rodent tail-skin temperature is an indirect surrogate that may not fully replicate human menopausal thermoregulatory dysfunction or clinical drug safety.
Cited by
- context A large number of the side effects and symptoms of menopause are caused by the loss of estrogen receptor beta (ERβ) activation.